The samples will be shipped for the approval of the US FDA before it can introduce the products.
Glenmark has invested about $20m in the plant that has an initial capacity of a million tables per year meant for exports to the US and UK.
It is hoping to get a USFDA approval for the plant within a year, which will be crucial for its revenue growth from 2012 since the firm estimates it will run out of capacity in its existing manufacturing units within a year or so.
Currently, Glenmark has three plants in western India – one for the manufacturing of solids, one for semi solids and one for hormones. Its existing USFDA approved units cater to the US and UK markets presently.